Analyzing Neumora Therapeutics (NMRA) and Its Competitors

Neumora Therapeutics (NASDAQ:NMRA) is one of 296 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its competitors? We will compare Neumora Therapeutics to similar companies based on the strength of its dividends, valuation, earnings, analyst recommendations, risk, profitability and institutional ownership.

Profitability

This table compares Neumora Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-73.63%	-68.97%
Neumora Therapeutics Competitors	-4,764.90%	-166.08%	-43.45%

Valuation & Earnings

This table compares Neumora Therapeutics and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Neumora Therapeutics	N/A	-$235.93 million	-5.21
Neumora Therapeutics Competitors	$547.30 million	-$36.47 million	3.45

Neumora Therapeutics’ competitors have higher revenue and earnings than Neumora Therapeutics. Neumora Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Neumora Therapeutics has a beta of 3.92, meaning that its stock price is 292% more volatile than the S&P 500. Comparatively, Neumora Therapeutics’ competitors have a beta of 1.13, meaning that their average stock price is 13% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Neumora Therapeutics and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	0	2	5	0	2.71
Neumora Therapeutics Competitors	1732	5065	13188	260	2.59

Neumora Therapeutics presently has a consensus target price of $21.67, indicating a potential upside of 122.45%. As a group, “Biological products, except diagnostic” companies have a potential upside of 65.48%. Given Neumora Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Neumora Therapeutics is more favorable than its competitors.

Institutional & Insider Ownership

47.7% of Neumora Therapeutics shares are held by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 26.4% of Neumora Therapeutics shares are held by company insiders. Comparatively, 16.0% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Neumora Therapeutics beats its competitors on 7 of the 13 factors compared.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson’s disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.